e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer
M. H. Jung, H. K. Kim, C. H. Oak, T. W. Jang, C. H. Jeon (Busan, Daegu, Republic Of Korea)
Source:
Annual Congress 2005 - Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Thematic Poster Session
Number:
595
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. H. Jung, H. K. Kim, C. H. Oak, T. W. Jang, C. H. Jeon (Busan, Daegu, Republic Of Korea). Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer. Eur Respir J 2005; 26: Suppl. 49, 595
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 771s
Year: 2006
Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
Source: Eur Respir Rev 2013; 22: 565-576
Year: 2013
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 75s
Year: 2004
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
Proliferative activity of non-small cell lung cancer after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 328s
Year: 2005
Survival of elderly patients with non-small lung cancer tretaed with combined chemotherapy and radiotherapy
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 244–259
Year: 2009
Combined radiotherapy for nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Adjuvant chemotherapy in stage IB nonsmall cell lung cancer
Source: Breathe 2009; 5: 361
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept